Robert Nelsen - 15 Oct 2026 Form 3 Insider Report for CITY THERAPEUTICS, INC. (CTY)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: CTY
Reported as of: 15 Oct 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 15 Oct 2026, 21:07:01 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mary Beth DeLena, Attorney-in-Fact

Key filing fact

Robert Nelsen filed Form 3 for CITY THERAPEUTICS, INC. (CTY) on 15 Oct 2026.

Key facts

This page summarizes Robert Nelsen's Form 3 filing for CITY THERAPEUTICS, INC. (CTY).
0 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 15 Oct 2026, 21:07.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001219042 Primary reporting owner

NELSEN ROBERT

Relationship: Director, 10%+ Owner
Address: 399 BINNEY STREET, CAMBRIDGE
Signature: /s/ Mary Beth DeLena, Attorney-in-Fact
Signature date: 15 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTY holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,718,292
Date: 15 Oct 2026
Ownership: By ARCH Venture Fund XII, L.P.
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTY holding Derivative

Series Seed convertible preferred stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 15 Oct 2026
Ownership: By ARCH Venture Fund XII, L.P.
Underlying class: Common Stock
Underlying amount: 3,294,900
Exercise price
Footnotes: F1, F2

CTY holding Derivative

Series A convertible preferred stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 15 Oct 2026
Ownership: By ARCH Venture Fund XII, L.P.
Underlying class: Common Stock
Underlying amount: 5,482,309
Exercise price
Footnotes: F1, F2

CTY holding Derivative

Series B convertible preferred stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 15 Oct 2026
Ownership: By ARCH Venture Fund XII, L.P.
Underlying class: Common Stock
Underlying amount: 2,027,006
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein, if any.

Footnote F2

Each share of Series Seed convertible preferred stock, Series A convertible preferred stock and Series B convertible preferred stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-to-1.0983 basis at the option of the holder, and will convert automatically upon the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Preferred Stock has no expiration date.

SEC remarks

Exhibit 24 - Power of Attorney